From Baxter Meeting..."In the kidney care separation we are very advanced in the dual pathway, which is potential sale of the business to a private equity investor but also a spinoff of the business as a publicly traded company. So we continue to make progress on both fronts and we are actually very advanced in the separation process and we are committed to separating in the second-half of 2024."